The STEP 8 trial compares the efficacy of once-daily subcutaneous liraglutide with weekly semaglutide on reducing weight in overweight and obese patients. Take this Journal Club CE to learn the strengths and limitations of the study, and how the findings impact practice and patient outcomes.

Upon successful completion of this application-based course, pharmacists and pharmacy students should be able to:
1. Compare the efficacy of weekly semaglutide and daily liraglutide on reducing weight in persons overweight and obese.
2. Compare the adverse effects of semaglutide and liraglutide when used in persons overweight and obese.
3. Describe the strengths and limitations of the STEP 8 Randomized Clinical Trial.
4. Identify patients who may be a candidate to receive semaglutide for weight management
5. Select the best glucagon-like peptide-1 analogue for weight management in a given patient

Courtney Selby, PharmD
Assistant Professor of Pharmacy Practice
Harding University College of Pharmacy

Courtney Selby has no relevant financial relationships to disclose. 

To obtain 1 contact hour of continuing pharmacy education credit (0.1 CEU), participants must read:

Rubino DM, Greenway FL, Khalid U, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022;327(2):138–150. doi:10.1001/jama.2021.23619

*CEimpact provides you with two (2) opportunities to complete the exam. If there are two failed attempts, the participant will not receive CPE credit.

Fee includes course, course materials, and CPE credit submission to CPE Monitor.
Course is non-refundable.
Initial Release Date: July 20, 2022
Planned Expiration Date: July 20, 2025

RV2-4.24